Literature DB >> 15367832

Severe sinus bradycardia after initiation of bupropion therapy: a probable drug-drug interaction with metoprolol.

David L McCollum1, Jerica L Greene, Darren K McGuire.   

Abstract

Bupropion is an increasingly prescribed agent to aid in smoking cessation. However it has important drug-drug interactions related to the cytochrome P450 system. One of these is its inhibition of the metabolism of the commonly used beta-blocker, metoprolol. The authors describe a case of severe bradycardia related to the addition of bupropion to the medical regimen of a patient on metoprolol.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15367832     DOI: 10.1023/B:CARD.0000041254.15807.98

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  5 in total

Review 1.  Clinically significant drug interactions with newer antidepressants.

Authors:  Edoardo Spina; Gianluca Trifirò; Filippo Caraci
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

2.  Clinically significant psychotropic drug-drug interactions in the primary care setting.

Authors:  Brett A English; Marcus Dortch; Larry Ereshefsky; Stanford Jhee
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

3.  Getting the balance right: Established and emerging therapies for major depressive disorders.

Authors:  Bojana Perović; Marija Jovanović; Branislava Miljković; Sandra Vezmar
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

4.  Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model.

Authors:  Caifu Xue; Xunjie Zhang; Weimin Cai
Journal:  Pharmaceutics       Date:  2017-12-21       Impact factor: 6.321

5.  Co-prescription of metoprolol and CYP2D6-inhibiting antidepressants before and after implementation of an optimized drug interaction database in Norway.

Authors:  Ane Gedde-Dahl; Olav Spigset; Espen Molden
Journal:  Eur J Clin Pharmacol       Date:  2022-07-25       Impact factor: 3.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.